Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies (DiAPREV-IT2)
Double-blind, Investigator-initiated Study to Determine the Effect of Alum-GAD (Diamyd) in Combination With Vitamin D3 on the Progression to Type 1 Diabetes in Children With Multiple Islet Autoantibodies
Sponsor: Lund University
Terminated
The study was interrupted early and terminated when only 26 out of 80 patients were enrolled due to new clinical study results indicating that the current study would not be informative.
Other terminated trials from Lund University
Other Diabetes Mellitus, Type 1 trials with similar outcome
A PHASE2 clinical study on Diabetes Mellitus, Type 1 and Prediabetic State, this trial is terminated or withdrawn. The trial is conducted by Lund University and has accumulated 12 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2020 — Nov 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Sep 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lund University
- Region Skane
For direct contact, visit the study record on ClinicalTrials.gov .